ETOP IBCSG Partners Foundation

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, ETOP IBCSG Partners Foundation sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials none currently recruiting 5 completed later-stage tilt upper quartile by trial count

ETOP IBCSG Partners Foundation: 6 sponsored US clinical trials, none currently recruiting.

ETOP IBCSG Partners Foundation sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 5 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Early Breast Cancer, with 1 trials.

Upper-quartile sponsor footprint

ETOP IBCSG Partners Foundation sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

6 total, page 1 of 1

ACTIVE NOT RECRUITING NA

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

NCT02308085
COMPLETED Phase 3

Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

NCT00659373
COMPLETED Phase 3

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

NCT00553410
COMPLETED Phase 3

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690
COMPLETED Phase 3

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066703
COMPLETED Phase 3

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer

NCT00074152

Phase Distribution

PhaseTrial count
Phase 3 5

Therapeutic Areas

Early Breast Cancer 1
Breast Cancer 1

How the ETOP IBCSG Partners Foundation archive is shaped

6 indexed studies, none listed as recruiting (0% open); 5 completed (83%).

Phase mix: 5 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Early Breast Cancer (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

ETOP IBCSG Partners Foundation: archived-pipeline peers nationwide

Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

ETOP IBCSG Partners Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share ETOP IBCSG Partners Foundation23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch10xBio22nd Century Group3-C Institute for Social Development3 Waves Wellness
ETOP IBCSG Partners Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

ETOP IBCSG Partners Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this ETOP IBCSG Partners Foundation page

6 registered trials is a research-attention snapshot, not an endorsement of ETOP IBCSG Partners Foundation or any single study.

  • None of ETOP IBCSG Partners Foundation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Early Breast Cancer is the condition ETOP IBCSG Partners Foundation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Early Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. ETOP IBCSG Partners Foundation pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.